Discover the Shionogi Phase 3 clinical trial of Zatolmilast (formerly led by Tetra Therapeutics) for Fragile X syndrome. Learn how this breakthrough PDE4D inhibitor improves cognition, behavior, and quality of life in individuals with Fragile X. Find recruiting sites and enrollment details today.
Read moreGurney, Mark
Positive Results Reported in Phase II Fragile X Clinical Trial of PDE4D Inhibitor Zatolmilast from Tetra Therapeutics
Today, Tetra Therapeutics announces the first unequivocally positive phase 2 clinical trial in Fragile X syndrome, press release below. The results do not depend on carving out a subset of patients or post hoc analysis.
Read more